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In a recent issue of Critical Care, Meyer and colleagues 
[1] report interesting surveillance data from ICUs in 30 
German hospitals, based on a large amount of 
microbiology and pharmacy data gathered between 2001 
and 2008. One of the main study ﬁ  ndings is a decreasing 
rate of methicillin-resistant Staphylococcus aureus 
(MRSA) and a dramatic increase of third generation 
cephalosporin (3GC) resistant Enterobacteriaceae over 
the study period. In recent years, most European 
countries have succeeded in reducing the burden of 
disease caused by MRSA [2,3].Th   is progress has, however, 
been partly oﬀ  set by the increase across Europe in the 
prevalence of multiresistant Gram-negative pathogens 
producing extended-spectrum betalactamases (ESBLs) 
or carbapenemases [4].
Th   e current study conﬁ  rms this worrisome ﬁ  nding and 
also shows an increase in carbapenem, 3GC and ﬂ  uoro-
quinolone use in German ICUs with a stable volume of 
overall antibiotic use. Th  e latter two antibiotic classes 
have been repeatedly identiﬁ  ed as risk factors for carriage 
of multidrug resistant Gram-negatives [5,6]. Carba-
penems on the other hand are ﬁ  rst-line drugs for the 
treatment of infections due to ESBL-producing bacteria. 
It is tempting to assume that overuse of ﬂ  uoro  quinolones 
and 3GC antibiotics contributed to the observed increase 
in ESBL producers, which subse  quently increased 
carbapenem use.
Th  e ecological nature of the data, however, makes it 
diﬃ   cult to infer clear cause-and-eﬀ  ect relationships [7], 
as does the failure to diﬀ  erentiate between hospital- and 
community-acquired isolates and clinical versus sur-
veillance cultures [8]. In addition, the analysis of trends is 
hampered by variation in the number of participating 
ICUs over time. Nevertheless, the increased burden of 
multidrug-resistant Gram-negative bacteria is a real 
phenomenon.
In contrast to MRSA, ESBL producers - notably strains 
of  Escherichia coli carrying plasmids of the CTX-M 
family - are mostly imported from the community into 
the hospital. Assuming a relationship with antibiotic use 
in animals and subsequent transmission of antibiotic 
resistant E. coli via the food chain is alluring, but strong 
epidemiological evidence is still lacking [9,10]. 
Transmission of ESBL-producing organisms within 
families might also contribute to the spread [11]. Th  e 
recently started European Union-funded SATURN 
project (Impact of Speciﬁ  c Antibiotic Th  erapies on the 
prevalence of hUman host ResistaNt bacteria) will gather 
more information on these risk factors.
As mentioned above, antibiotic overuse in humans 
probably plays a central role in the spread of ESBL 
producers. In the context of this study it is noteworthy 
that Germany has a relatively high level of ﬂ  uoro-
quinolone use in the community [12]. As to antibiotic use 
in hospitals, the overall quantity of antibiotic use in 
German ICUs is comparable to that of other countries 
[13]. What about the quality of antibiotic prescribing? 
Although there is important heterogeneity between 
ICUs, inappropriate antibiotic use is still common in 
Germany (as in many other countries), where infectious 
diseases as a stand-alone speciality and antibiotic 
stewardship programmes are still underdeveloped [14].
Compared to other European countries or highly 
publicised health threats, such as bioterrorism and swine 
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control multidrug-resistant microorganisms has been 
slow to rise in Germany. Only recently (2009) has a 
German reference centre for surveillance of Gram-
negative bacteria been established [15], which focuses, 
among other things, on detection of carbapenemase-
producing bacteria. A ﬁ  rst outbreak of carbapenemase-
producing  Klebsiella pneumoniae in Germany has 
recently been reported, probably linked to an index 
patient with previous healthcare contact in Greece [16]. 
Th  e fact that two ICUs in 2008 reported carbapenem-
resistant K. pneumoniae in the current study raises the 
concern that these strains might already be more 
common in Central Europe than previously assumed 
since detection of these strains may be diﬃ   cult  with 
routine laboratory techniques [17].
How can we control the rise of multidrug-resistant 
Gram-negatives? With regard to ESBL-producers the 
growing community reservoir makes it unlikely that we 
will be able to control the spread by conventional 
measures targeted at nosocomial infection control. Th  e 
promotion of prudent antibiotic use in the community 
and animal husbandry should therefore be a key priority. 
As to carbapenemase-producing Enterobacteriaceae, 
early identiﬁ  cation of these strains and aggressive infec-
tion control measures seem essential [18]. Examin  ing 
novel decolonization strategies for Gram-negative Entero-
bacteriacae might be a further strategy worth evaluating. 
If we manage to enforce all these measures, we will 
hopefully be able to think positive again - even with 
regard to Gram-negatives.
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